SIRS Therapeutics and F4 Pharma announce collaboration with US company Partner Therapeutics PTx to explore potential uses of FX06 in Biodefense applications

Munich-based SIRS Therapeutics GmbH and Vienna-based F4 Pharma GmbH today announced the signature of a licensing and collaboration agreement with Massachusetts-based company Partner Therapeutics PTx. While F4 Pharma and SIRS are jointly developing FX06 in diseases associated with capillary leak – focusing on the treatment of severe COVID-19 for the time being, the potential of FX06 is going far beyond this use. Within the collaboration, the partners will explore the potential of US Government contracts and grant funding especially concentrating on chemical, biological, radiological, and nuclear countermeasure indications.

“We are excited to work with Partner Therapeutics, given their impressive track record in late stage development in the area of medical countermeasures for bio-threats and their industry experienced development team. In collaboration with Partners Therapeutics we are focused on exploring FX06 in areas of high interest and medical need,” said Anne Burger, CEO of SIRS Therapeutics.

Thomas Steiner, CEO and co-founder of F4 Pharma “the cooperation with PTx is another successful milestone in our efforts to serve critical ill patients in various serious indications. We are looking forward to addressing unmet medical needs and to starting our joint activity at the earliest.”

Petra Wülfroth, CSO and co-founder of F4 Pharma “The current SARS-CoV-2 pandemic has highlighted the public vulnerability caused by viruses, however, other biological or chemical threat agents can also evolve into a major public concern. FX06 has a broad applicability in diseases and pathological conditions caused by systemic inflammation and increased permeability of the blood vessels.”  She added, “We believe its mechanism of action makes it a promising tool to protect people.”

“We look forward to the opportunity to work with our partners at SIRS and F4 Pharma to advance the development of FX06 as a potentially important treatment for COVID-19 as well as future pandemic threats and unmet needs for medical countermeasures,” said John McManus, Chief Business Officer at Partner Therapeutics. “We believe that FX06’s activity in both animal and human models could make it a powerful potential tool for both known and unknown threats.”

ABOUT SIRS THERAPEUTICS

SIRS Therapeutics GmbH is a development stage biopharmaceutical company that develops FX06, a fibrin-derived peptide for the treatment of diseases related to capillary leakage e.g., ARDS in patients with underlying COVID-19 infection. The company was founded with initial investments from Wellington Partners in 2020 and is located in Germany. Visit www.sirs-therapeutics.com

ABOUT F4 PHARMA

F4 Pharma is a privately owned Austrian biotechnology company focusing on the development of the platform molecule FX06 in several indications with high unmet medical need. It is the intention of F4 Pharma to provide a safe and efficacious therapy to patients and physicians in critical disease situations in intensive care. Visit www.f4-pharma.com

ABOUT PARTNER THERAPEUTICS

PTx is an integrated biotechnology company focused on the development and commercialization of late-stage therapeutics that improve health outcomes in the treatment of cancer and other serious diseases. The company believes in delivering products and supporting medical teams with the purpose of achieving superior outcomes for patients and their families. Visit www.partnertx.com

ABOUT FX06

The endothelium, i.e. the inner layer of the blood vessels, plays an important role in the homeostasis between the blood within the vessel and the surrounding tissue. In many pathological disease situations, this well-balanced equilibrium is disturbed causing an increased permeability of the blood vessel and allowing inflammatory cells to invade into the surrounding tissue. The synthetic peptide FX06 binds to the contact points between the cells, normalizes increased permeability and reduces the systemic inflammation of the endothelium.

Contact:

Business:
Mag.Thomas Steiner
F4 Pharma GmbH
thomas.steiner@f4-pharma.com
Tel +43 6641107694

Science:
Dr. Petra Wülfroth
F4 Pharma GmbH
petra.wuelfroth@f4-pharma.com
Mobile +41 79 788 1800

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.